Posted by Michael Wonder on 23 Feb 2025
HIRA to remove 17 medicines from group 2 anti-cancer list, update reimbursement criteria
21 February 2025 - Korea's HIRA said it has decided to remove 17 medicines from the list of group 2 anti-cancer drugs that have not been reclassified since their initial listing.
On Thursday, HIRA announced an amendment to the list of group 2 anti-cancer medicines, deleting 17 medicines from the list and changing the reimbursement criteria for some medicines.
The move, which is aimed at overhauling the reimbursement system and reflecting the latest clinical evidence, will take effect on 1 March 2025.
The medicines that will be deleted from the list of group 2 anti-cancer medicines are:
- Paclitaxel (nanoparticle albumin bound)
- Aldesleukin
- Anagrelide
- Anastrozole
- Belotecan
- Capecitabine
- Enocitabine
- Exemestane
- Heptaplatin (non-reimbursed)
- Ibritumomab tiuxetan (non-reimbursed)
- Irinotecan hydrochloride trihydrate
- Letrozole
- Doxorubicin hydrochloride (liposomal)
- Oxaliplatin
- Pemetrexed disodium heptahydrate
- Tegafur with gimeracil and oteracil
- Topotecan hydrochloride
